Topic
chemical compound
Also known as (R)-crizotinib, PF 2341066, PF-02341066, PF-2341066, PF2341066, Xalkori®
GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.
No public IJR answers mention crizotinib yet. As people ask about it and share their answers, they'll appear here.